Aurora Borealis (Bora), Which Promotes Plk1 Activation by Aurora A, Has an Oncogenic Role in Ovarian Cancer

Alfonso Parrilla, Marta Barber, Blanca Majem Cavaller, Josep Castellvi, Juan Morote Robles, José Luis Sánchez, Assumpció Pérez-Benavente, Miguel F. Segura, Antonio Gil-Moreno, Anna Santamaría

Producción científica: Contribución a una revistaArtículoInvestigaciónrevisión exhaustiva

13 Citas (Scopus)

Resumen

Identifying novel actionable factors that critically contribute to tumorigenesis is essential in ovarian cancer, an aggressive and disseminative tumor, with limited therapeutic options available. Here we show that Aurora Borealis (BORA), a mitotic protein that plays a key role in activating the master mitotic kinase polo-like kinase 1 (PLK1), has an oncogenic role in ovarian cancer. Gain and loss of function assays on mouse models and ex vivo patient-derived ascites cultures revealed an oncogenic role of BORA in tumor development and a transcriptome-analysis in clinically representative models depicted BORA's role in survival, dissemination and inflammatory cancer related-pathways. Importantly, combinatory treatments of FDA-approved inhibitors against oncogenic downstream effectors of BORA displayed synergistic effect in ovarian cancer models, offering promising therapeutic value. Altogether, our findings uncovered for the first time a critical role of BORA in the viability of human cancer cells providing potential novel therapeutic opportunities for ovarian cancer management
Idioma originalInglés
PublicaciónCancers
Volumen12
DOI
EstadoPublicada - 2020

Huella

Profundice en los temas de investigación de 'Aurora Borealis (Bora), Which Promotes Plk1 Activation by Aurora A, Has an Oncogenic Role in Ovarian Cancer'. En conjunto forman una huella única.

Citar esto